Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells

References

• Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037-44; PMID:16505422; https://doi.org/10.1200/JCO.2005.02.6914
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; https://doi.org/10.1056/NEJMra1001389
   PubMed Web of Science ®Google Scholar
• Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996; 74:874-80; PMID:8826852; https://doi.org/10.1038/bjc.1996.451
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75; PMID:12432043; https://doi.org/10.1056/NEJMoa021153
   PubMed Web of Science ®Google Scholar
• Fadare O, Tavassoli FA. Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Practice Oncol 2008; 5:149-59; PMID:18212769; https://doi.org/10.1038/ncponc1038
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; https://doi.org/10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411:1017-21; PMID:11429595; https://doi.org/10.1038/35082500
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011; 108:3761-6; PMID:21321214; https://doi.org/10.1073/pnas.1014835108
   PubMed Web of Science ®Google Scholar
• Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012; 209:679-96; PMID:22430491; https://doi.org/10.1084/jem.20111512
   PubMed Web of Science ®Google Scholar
• Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol 2014; 26:568-75; PMID:25188473; https://doi.org/10.1097/CCO.0000000000000129
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery 2015; 14:130-46; PMID:25633797; https://doi.org/10.1038/nrd4504
   PubMed Web of Science ®Google Scholar
• Aleem E, Berthet C, Kaldis P. Cdk2 as a master of S phase entry: fact or fake? Cell Cycle 2004; 3:35-7; PMID:14657662; https://doi.org/10.4161/cc.3.1.632
   PubMed Web of Science ®Google Scholar
• Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H, Kaldis P. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 2006; 10:563-73; PMID:16678773; https://doi.org/10.1016/j.devcel.2006.03.004
   PubMed Web of Science ®Google Scholar
• Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, Seki T, Matsui H, Fujisawa J, Okazaki K. Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 2007; 67:5090-6; PMID:17545585; https://doi.org/10.1158/0008-5472.CAN-06-4629
   PubMed Web of Science ®Google Scholar
• Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-31; PMID:15241418; https://doi.org/10.1038/nature02650
   PubMed Web of Science ®Google Scholar
• Cooley A, Zelivianski S, Jeruss JS. Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines. Cell Cycle 2010; 9:4900-7; PMID:21150326; https://doi.org/10.4161/cc.9.24.14158
   PubMed Web of Science ®Google Scholar
• Zelivianski S, Cooley A, Kall R, Jeruss JS. Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells. Mol Cancer Res 2010; 8:1375-87; PMID:20736297; https://doi.org/10.1158/1541-7786.MCR-09-0537
   PubMed Web of Science ®Google Scholar
• Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP, Thomas A, Shea LD, Jeruss JS. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells. Cell Cycle 2014; 13:3191-201; PMID:25485498; https://doi.org/10.4161/15384101.2014.950126
   PubMed Web of Science ®Google Scholar
• Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, Macias MJ, Erdjument-Bromage H, Tempst P, Massague J. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell 2009; 36:457-68; PMID:19917253; https://doi.org/10.1016/j.molcel.2009.09.043
   PubMed Web of Science ®Google Scholar
• Aragon E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massague J, Macias MJ. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 2011; 25:1275-88; PMID:21685363; https://doi.org/10.1101/gad.2060811
   PubMed Web of Science ®Google Scholar
• Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M, Hanai J, Akiyama H, Abe M, Miyazono K, et al. Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 2009; 284:6109-15; PMID:19122240; https://doi.org/10.1074/jbc.M804659200
   PubMed Web of Science ®Google Scholar
• Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, Liu F. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 2010; 285:1754-64; PMID:19920136; https://doi.org/10.1074/jbc.M109.063826
   PubMed Web of Science ®Google Scholar
• Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001; 20:3459-72; PMID:11432833; https://doi.org/10.1093/emboj/20.13.3459
   PubMed Web of Science ®Google Scholar
• Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007; 8:904-16; PMID:17878917; https://doi.org/10.1038/nrm2261
   PubMed Web of Science ®Google Scholar
• Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, Wang DG. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 2004; 164:1727-37; PMID:15111319; https://doi.org/10.1016/S0002-9440(10)63731-5
   PubMed Web of Science ®Google Scholar
• Blake DG, MacKay C, Frame S, Zheleva D. CYC065, a novel CDK2/9 inhibitor: Molecular basis for clinical development in basal-like triple-negative breast cancer. Cancer Res 2016; 76(4 Suppl):Abstract nr P5-03-10; https://doi.org/10.1158/1538-7445.SABCS15-P5-03-10
   Web of Science ®Google Scholar
• Chen CR, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002; 110:19-32; PMID:12150994; https://doi.org/10.1016/S0092-8674(02)00801-2
   PubMed Web of Science ®Google Scholar
• Feng XH, Liang YY, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 2002; 9:133-43; PMID:11804592; https://doi.org/10.1016/S1097-2765(01)00430-0
   PubMed Web of Science ®Google Scholar
• Rustighi A, Zannini A, Campaner E, Ciani Y, Piazza S, Del Sal G. PIN1 in breast development and cancer: a clinical perspective. Cell Death Differ 2017; 24:200-11; PMID:27834957; https://doi.org/10.1038/cdd.2016.122
   PubMed Web of Science ®Google Scholar
• Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20:79-91; PMID:21741598; https://doi.org/10.1016/j.ccr.2011.06.004
   PubMed Web of Science ®Google Scholar
• Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med 2014; 6:99-119; PMID:24357640; https://doi.org/10.1002/emmm.201302909
   PubMed Web of Science ®Google Scholar
• Luo ML, Gong C, Chen CH, Lee DY, Hu H, Huang P, Yao Y, Guo W, Reinhardt F, Wulf G, et al. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer. Cancer Res 2014; 74:3603-16; PMID:24786790; https://doi.org/10.1158/0008-5472.CAN-13-2785
   PubMed Web of Science ®Google Scholar
• Ryo A, Uemura H, Ishiguro H, Saitoh T, Yamaguchi A, Perrem K, Kubota Y, Lu KP, Aoki I. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res 2005; 11:7523-31; PMID:16243827; https://doi.org/10.1158/1078-0432.CCR-05-0457
   PubMed Web of Science ®Google Scholar
• Tan X, Zhou F, Wan J, Hang J, Chen Z, Li B, Zhang C, Shao K, Jiang P, Shi S, et al. Pin1 expression contributes to lung cancer: Prognosis and carcinogenesis. Cancer Biol Therapy 2010; 9:111-9; https://doi.org/10.4161/cbt.9.2.10341
   PubMed Web of Science ®Google Scholar
• Atabay KD, Yildiz MT, Avsar T, Karabay A, Kilic T. Knockdown of Pin1 leads to reduced angiogenic potential and tumorigenicity in glioblastoma cells. Oncol Letters 2015; 10:2385-9; PMID:26622856
   PubMed Web of Science ®Google Scholar
• Jo E, Park SJ, Choi YS, Jeon WK, Kim BC. Kaempferol Suppresses Transforming Growth Factor-beta1-Induced Epithelial-to-Mesenchymal Transition and Migration of A549 Lung Cancer Cells by Inhibiting Akt1-Mediated Phosphorylation of Smad3 at Threonine-179. Neoplasia 2015; 17:525-37; PMID:26297431; https://doi.org/10.1016/j.neo.2015.06.004
   PubMed Web of Science ®Google Scholar
• Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS One 2011; 6:e26514; PMID:22028892; https://doi.org/10.1371/journal.pone.0026514
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19:156-72; PMID:19153598; https://doi.org/10.1038/cr.2009.5
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chinese J Cancer 2011; 30:603-11; PMID:21880181; https://doi.org/10.5732/cjc.011.10226
   PubMedGoogle Scholar
• Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278:21113-23; PMID:12665527; https://doi.org/10.1074/jbc.M211304200
   PubMed Web of Science ®Google Scholar
• Dzwonek J, Preobrazhenska O, Cazzola S, Conidi A, Schellens A, van Dinther M, Stubbs A, Klippel A, Huylebroeck D, ten Dijke P, et al. Smad3 is a key nonredundant mediator of transforming growth factor beta signaling in Nme mouse mammary epithelial cells. Mol Cancer Res 2009; 7:1342-53; PMID:19671686; https://doi.org/10.1158/1541-7786.MCR-08-0558
   PubMed Web of Science ®Google Scholar
• Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 2009; 11:943-50; PMID:19597490; https://doi.org/10.1038/ncb1905
   PubMed Web of Science ®Google Scholar
• Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001; 3:793-801; PMID:11533658; https://doi.org/10.1038/ncb0901-793
   PubMed Web of Science ®Google Scholar
• Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell 2008; 19:4875-87; PMID:18799618; https://doi.org/10.1091/mbc.E08-05-0506
   PubMed Web of Science ®Google Scholar
• Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene 2008; 27:5075-80; PMID:18469861; https://doi.org/10.1038/onc.2008.140
   PubMed Web of Science ®Google Scholar
• Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, Hakamada K, Sasaki M, Kijima H. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 2007; 20:139-43; PMID:17611630
   PubMed Web of Science ®Google Scholar
• Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999; 18:5311-7; PMID:10498883; https://doi.org/10.1038/sj.onc.1202998
   PubMed Web of Science ®Google Scholar
• Sengupta S, Biarnes MC, Jordan VC. Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Res Treatment 2014; 143:113-24; PMID:24309997; https://doi.org/10.1007/s10549-013-2789-2
   PubMed Web of Science ®Google Scholar
• Farrell AS, Pelz C, Wang X, Daniel CJ, Wang Z, Su Y, Janghorban M, Zhang X, Morgan C, Impey S, et al. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. Mol Cell Biol 2013; 33:2930-49; PMID:23716601; https://doi.org/10.1128/MCB.01455-12
   PubMed Web of Science ®Google Scholar
• Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, et al. FDA Approval: Palbociclib for the treatment of Postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 2015; 21:4760-6; PMID:26324739; https://doi.org/10.1158/1078-0432.CCR-15-1185
   PubMed Web of Science ®Google Scholar
• Liu L, Michowski W, Inuzuka H, Shimizu K, Nihira NT, Chick JM, Li N, Geng Y, Meng AY, Ordureau A, et al. G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol 2017; 19:177-88; PMID:28192421; https://doi.org/10.1038/ncb3474
   PubMed Web of Science ®Google Scholar
• Sajadimajd S, Yazdanparast R. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells. Apoptosis 2017; 22:135-44; PMID:27770268; https://doi.org/10.1007/s10495-016-1291-9
   PubMed Web of Science ®Google Scholar
• Min SH, Zhou XZ, Lu KP. The role of Pin1 in the development and treatment of cancer. Arch Pharmacal Res 2016; 39:1609-20; PMID:27572155; https://doi.org/10.1007/s12272-016-0821-x
   PubMed Web of Science ®Google Scholar